The Alzheimer’s Research UK Oxford Drug Discovery Institute (ODDI) couples the deep disease knowledge and biology expertise of the academic community with high quality, innovative drug discovery technologies. This initiative is based on juxtaposing high quality drug discovery expertise alongside a deep scientific and academic understanding of patients, disease mechanisms, and model systems. The intent is to translate cutting edge academic science into drug discovery, and to prosecute projects from target to lead status, and beyond.
Housed within The Target Discovery Institute at the University of Oxford, the ODDI is uniting collaborative efforts for target identification with sophisticated target development capabilities. Led by the CSO, Dr John Davis, the ODDI focuses on novel targets in the dementia therapeutic area, bringing together researchers from Biology, Chemistry, Psychiatry, and Neuroscience. The institute is part of a newly formed, world-class, network of three drug discovery institutes, sponsored by Alzheimer’s Research UK.
The Oxford Drug Discovery Institute is one of three Institutes within the Alzheimer’s Research UK Drug Discovery Alliance, working alongside Institutes at the University of Cambridge and University College London. The Alliance will accelerate the discovery of novel, effective therapeutics for Alzheimer’s disease and other neurodegenerative diseases.
Alzheimer’s Research UK unites more than 1000 dementia researchers from across the UK to support and streamline dementia research. The charity is dedicated to funding the best minds and forging the most effective partnerships to nurture discovery and ideas, as well as translating findings from this pioneering research into benefits for people with dementia. For more information, visit ARUK’s website.
FORMA Therapeutics and the University of Oxford Announce Multi-Year Collaboration to Advance the Development of Deubiquitinating Enzyme (DUB) Inhibitors for the Treatment of Neurodegenerative Diseases
Oxford, U.K. and Watertown, Massachusetts, USA – May 9th, 2018 – FORMA Therapeutics and the University of Oxford announced today they have entered into a collaboration and license agreement to identify, validate and develop deubiquitinating enzyme (DUB) inhibitors for the treatment of neurodegenerative diseases..
Researchers in London have identified a promising approach for tackling the hallmark Alzheimer’s disease protein, tau. The findings of the research, which was funded by Alzheimer’s Research UK, are published today (Monday 7 May) in the scientific publication Acta Neuropathologica Communications.
The research team are now working with experts from the Alzheimer’s Research UK Oxford Drug Discovery Institute to further assess the potential of targeting TAOKs to treat diseases like Alzheimer’s, and to develop this work towards something that could help people with dementia.
Alzheimer’s Research UK Oxford Drug Discovery Institute has teamed up with the University of Manchester and the Phenomics Discovery Initiative to identify small molecule inhibitors of NLRP3 inflammasome.